New study tracks duchenne muscular dystrophy from birth to age 3
NCT ID NCT07092540
First seen Jun 27, 2026 · Last updated Aug 20, 2026 · Updated 2 times
Summary
This study follows 105 boys from birth to age 3 who have Duchenne muscular dystrophy (DMD), identified through newborn screening. Researchers will measure motor and cognitive skills over time to understand how the disease develops in early childhood. The goal is to gather information that could help design future treatments and care strategies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 105 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2026
- Expected to finish
-
Aug 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Males with genetically confirmed diagnosis of DMD (Duchenne Muscular Dystrophy)
- Ages
-
0 days to 3 years
- Sex
-
Male participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Male child between birth and 3.0 years of age at time of enrollment. * A confirmed and documented pathogenic or likely pathogenic variant in the DMD gene. * Ability of parent/guardian to understand and provide written informed consent (signing Parental Permission and Consent Form). * Willingness of parent/guardian to comply with the protocol Schedule of Activities, including all study site visits. Exclusion Criteria: * Female * Presence of any confirmed genetic disease, other than DMD, that could impact early development, which, in the opinion of the PI, may confound interpretation of developmental progress. * Presence of any significant medical condition (i.e., extreme prematurity, hypoxic ischemic encephalopathy) which, in the opinion of the PI, may confound interpretation of the clinical course of DMD. * Inability/unwillingness of parent/guardian to provide written permission (sign PPF) or to comply with the protocol Schedule of Activities.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Duchenne muscular dystrophy (DMD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
4 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Cincinnati Children's Hospital Medical Center
NOT_YET_RECRUITINGCincinnati, Ohio, 45226, United States
-
Nationwide Children's Hospital
RECRUITINGColumbus, Ohio, 43205, United States
-
Stony Brook Medicine
NOT_YET_RECRUITINGStony Brook, New York, 11794, United States
-
University of Rochester
RECRUITINGRochester, New York, 14618, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Three-Hour online class help families manage bladder and bowel issues in duchenne muscular dystrophy?
- Can a new drug help boys with duchenne muscular dystrophy build muscle protein?
- New drugs aim to slow muscle decline in duchenne muscular dystrophy
- AI-Powered heart scans aim to predict deadly complications in muscular dystrophy
- Wearable sensors could bring duchenne monitoring home
- Could a popular Weight-Loss drug help—or Harm—Those with duchenne muscular dystrophy?